复宏汉霖(02696.HK)：HLX17在多种已切除实体瘤患者中开展的国际多中心1期临床研究于中国境内完成首例患者给药

Core Viewpoint - The company has announced the completion of the first patient dosing in an international multicenter Phase 1 clinical study of its self-developed biosimilar HLX17 for various resected solid tumors in mainland China, excluding Hong Kong, Macau, and Taiwan [1] Group 1 - The biosimilar HLX17 is a recombinant humanized monoclonal antibody targeting PD-1 [1] - The company plans to conduct the international multicenter clinical trial in other countries/regions such as the United States, Europe, and Australia once conditions are met [1]